Merck announced successful outcomes from two phase III studies evaluating its oral PCSK9 inhibitor, enlicitide decanoate, in patients with high cholesterol on statin therapy. The drug demonstrated statistically significant and clinically meaningful reductions in LDL cholesterol across diverse patient populations, reinforcing Merck's potential entry into a crowded cholesterol-lowering market. These positive results propel enlicitide closer to potential regulatory approval and market launch amid competitive therapies.